|1.||Furuta, Yousuke: 16 articles (09/2015 - 06/2009)|
|2.||Gowen, Brian B: 11 articles (09/2015 - 06/2009)|
|3.||Smee, Donald F: 11 articles (09/2015 - 06/2009)|
|4.||de Lamballerie, Xavier: 4 articles (11/2015 - 05/2014)|
|5.||De Clercq, Erik: 4 articles (01/2015 - 01/2008)|
|6.||Morrey, John D: 4 articles (04/2012 - 06/2009)|
|7.||Günther, Stephan: 3 articles (11/2015 - 05/2014)|
|8.||Oestereich, Lisa: 3 articles (11/2015 - 05/2014)|
|9.||Westover, Jonna B: 3 articles (09/2015 - 04/2014)|
|10.||Barnard, Dale L: 3 articles (06/2014 - 06/2009)|
01/01/2015 - "Favipiravir remained highly effective against lethal LASV infection when treatments were initiated nine days post-infection, a time when animals were demonstrating advanced signs of disease. "
04/01/2014 - "Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model."
01/01/2013 - "To evaluate the efficacy of favipiravir in vivo, guinea pigs were challenged with the pathogenic Romero strain of JUNV, and then treated twice daily for two weeks with oral or intraperitoneal (i.p.) favipiravir (300 mg/kg/day) starting 1-2 days post-infection. "
01/01/2014 - "In this study, we show that the broad-range antiviral nucleoside favipiravir reduces viral load in vivo by exerting antiviral mutagenesis in a mouse model for norovirus infection. "
02/01/2011 - "A novel pyrazine derivative currently in clinical trials for the treatment of influenza virus infections, T-705 (favipiravir), has demonstrated broad-spectrum activity against a number of RNA viruses, including arenaviruses. "
|2.||Human Influenza (Influenza)
09/01/2015 - "Favipiravir (T-705) is a new anti-influenza drug approved for human use in Japan and progressing through Phase 3 clinical trials in the U.S. "
04/01/2014 - "Favipiravir or T-705 has broad antiviral activity and has already undergone phase II and is undergoing phase III clinical trials for influenza. "
11/01/2013 - "A Phase III clinical evaluation of favipiravir for influenza therapy has been completed in Japan and two Phase II studies have been completed in the United States. "
06/01/2010 - "In this study, favipiravir was evaluated in vitro for its ability to inhibit the replication of a representative panel of seasonal influenza viruses, the 2009 A(H1N1) strains, and animal viruses with pandemic (pdm) potential (swine triple reassortants, H2N2, H4N2, avian H7N2, and avian H5N1), including viruses which are resistant to the currently licensed anti-influenza drugs. "
04/01/2013 - "T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro."
|3.||Virus Diseases (Viral Diseases)
05/01/2010 - "Several studies have reported favipiravir (T-705) to be effective in treating a number of viral diseases modeled in rodent systems. "
11/01/2015 - "This review summarises attempts in identification, evaluation, and development of small-molecule candidates for treatment of Ebola viral disease, including the most promising experimental drugs brincidofovir (CMX001), BCX4430, and favipiravir (T-705). "
10/01/2011 - "Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever."
01/01/2013 - "Favipiravir (T-705) inhibits Junín virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever."
10/01/2011 - "Favipiravir (300 mg/kg/day, twice daily orally for 14 days) was highly effective, as all animals recovered fully from PICV-induced disease even when therapy was initiated one week after virus challenge when animals were already significantly ill with marked fevers and thrombocytopenia. "
02/01/2015 - "Favipiravir is a new antiviral medication that can be used in emerging viral pandemics such as Ebola virus, 2009 pandemic influenza H1N1 virus, Lassa fever, and Argentine hemorrhagic fever. "
05/01/2014 - "Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever."
|5.||Hantavirus Pulmonary Syndrome
|1.||Antiviral Agents (Antivirals)
|7.||cidofovir hexadecyloxypropyl ester
|9.||DNA Primase (Primase)